3oy3

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (09:45, 6 September 2023) (edit) (undo)
 
(6 intermediate revisions not shown.)
Line 1: Line 1:
-
{{Seed}}
 
-
[[Image:3oy3.jpg|left|200px]]
 
-
<!--
+
==Crystal structure of ABL T315I mutant kinase domain bound with a DFG-out inhibitor AP24589==
-
The line below this paragraph, containing "STRUCTURE_3oy3", creates the "Structure Box" on the page.
+
<StructureSection load='3oy3' size='340' side='right'caption='[[3oy3]], [[Resolution|resolution]] 1.95&Aring;' scene=''>
-
You may change the PDB parameter (which sets the PDB file loaded into the applet)
+
== Structural highlights ==
-
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
+
<table><tr><td colspan='2'>[[3oy3]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3OY3 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3OY3 FirstGlance]. <br>
-
or leave the SCENE parameter empty for the default display.
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.95&#8491;</td></tr>
-
-->
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=XY3:5-[(5-{[4-{[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]METHYL}-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYL}-2-METHYLPHENYL)ETHYNYL]-1-METHYL-1H-IMIDAZOLE-2-CARBOXAMIDE'>XY3</scene></td></tr>
-
{{STRUCTURE_3oy3| PDB=3oy3 | SCENE= }}
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3oy3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3oy3 OCA], [https://pdbe.org/3oy3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3oy3 RCSB], [https://www.ebi.ac.uk/pdbsum/3oy3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3oy3 ProSAT]</span></td></tr>
 +
</table>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/ABL1_MOUSE ABL1_MOUSE] Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-191' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks.<ref>PMID:8194526</ref> <ref>PMID:7780740</ref> <ref>PMID:9109492</ref> <ref>PMID:11279004</ref> <ref>PMID:11350980</ref> <ref>PMID:11279131</ref> <ref>PMID:12107171</ref> <ref>PMID:12748290</ref> <ref>PMID:14993293</ref> <ref>PMID:19903482</ref> <ref>PMID:19878872</ref>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
The BCR-ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia. However, drug resistance caused by kinase domain mutations has necessitated the development of new mutation-resistant inhibitors, most recently against the T315I gatekeeper residue mutation. Ponatinib (AP24534) inhibits both native and mutant BCR-ABL, including T315I, acting as a pan-BCR-ABL inhibitor. Here, we undertook a combined crystallographic and structure-activity relationship analysis on ponatinib to understand this unique profile. While the ethynyl linker is a key inhibitor functionality that interacts with the gatekeeper, virtually all other components of ponatinib play an essential role in its T315I inhibitory activity. The extensive network of optimized molecular contacts found in the DFG-out binding mode leads to high potency and renders binding less susceptible to disruption by single point mutations. The inhibitory mechanism exemplified by ponatinib may have broad relevance to designing inhibitors against other kinases with mutated gatekeeper residues.
-
===Crystal structure of ABL T315I mutant kinase domain bound with a DFG-out inhibitor AP24589===
+
Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance.,Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T, Dalgarno DC, Zhu X Chem Biol Drug Des. 2011 Jan;77(1):1-11. doi:, 10.1111/j.1747-0285.2010.01054.x. Epub 2010 Nov 30. PMID:21118377<ref>PMID:21118377</ref>
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 3oy3" style="background-color:#fffaf0;"></div>
-
<!--
+
==See Also==
-
The line below this paragraph, {{ABSTRACT_PUBMED_21118377}}, adds the Publication Abstract to the page
+
*[[Tyrosine kinase 3D structures|Tyrosine kinase 3D structures]]
-
(as it appears on PubMed at http://www.pubmed.gov), where 21118377 is the PubMed ID number.
+
== References ==
-
-->
+
<references/>
-
{{ABSTRACT_PUBMED_21118377}}
+
__TOC__
-
 
+
</StructureSection>
-
==About this Structure==
+
[[Category: Large Structures]]
-
3OY3 is a 2 chains structure with sequences from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3OY3 OCA].
+
-
 
+
-
==Reference==
+
-
<ref group="xtra">PMID:21118377</ref><references group="xtra"/>
+
[[Category: Mus musculus]]
[[Category: Mus musculus]]
-
[[Category: Non-specific protein-tyrosine kinase]]
+
[[Category: Clackson T]]
-
[[Category: Clackson, T.]]
+
[[Category: Commodore L]]
-
[[Category: Commodore, L.]]
+
[[Category: Dalgarno DC]]
-
[[Category: Dalgarno, D C.]]
+
[[Category: Huang WS]]
-
[[Category: Huang, W S.]]
+
[[Category: Keats J]]
-
[[Category: Keats, J.]]
+
[[Category: Rivera V]]
-
[[Category: Rivera, V.]]
+
[[Category: Shakespeare WC]]
-
[[Category: Shakespeare, W C.]]
+
[[Category: Thomas M]]
-
[[Category: Thomas, M.]]
+
[[Category: Wang Y]]
-
[[Category: Wang, Y.]]
+
[[Category: Xu Q]]
-
[[Category: Xu, Q.]]
+
[[Category: Zhou T]]
-
[[Category: Zhou, T.]]
+
[[Category: Zhu X]]
-
[[Category: Zhu, X.]]
+
-
[[Category: Atp binding]]
+
-
[[Category: Phosphorylation]]
+
-
[[Category: Phosphotransferase]]
+
-
[[Category: Protein kinase two-domain fold]]
+
-
[[Category: Protein-inhibitor complex]]
+
-
[[Category: Transferase-transferase inhibitor complex]]
+
-
 
+
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Dec 15 08:44:23 2010''
+

Current revision

Crystal structure of ABL T315I mutant kinase domain bound with a DFG-out inhibitor AP24589

PDB ID 3oy3

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools